2Dormandy JA, Charbonnel B, Ecldand DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial [J].Lancet, 2005, 366 (9493)1279-1289.
3Lewis JD, Ferrara A, Strom BL, et al. The risk of bladder cancer among diabetic patients treated with pioglitazone:analysis through April 30, 2008[R]. University of Pennsylvania and Kaiser Permanente Northern California Division of Research. Submitted to FDA, unpublished results.
